This webinar by Athina Metaxa, United Kingdom, and Hampus Yngwe, Sweden, was recorded on 7 March 2025 as part of the ‘A European perspective on psychedelics research, from pharmacology to clinical effects’ webinar series, organised by the ECNP Psychedelic Research Network.
In this last session we shift our focus to the current state of clinical research with a focus on the clinical effects in psychiatry. The talk discusses the application of psychedelics in different psychiatric disorders and will take a closer look at on-going clinical research using psilocybin for depression at Karolinska Institutet.
About the ‘A European perspective on psychedelics research, from pharmacology to clinical effects’ webinar series
In this webinar series, the wide scope of psychedelics research conducted at various centers in Europe is explored. Throughout three sessions, a wide range of topics is covered: from pharmacology and preclinical investigations to the clinical trials conducted in psychiatry. The sessions in this series build upon each other but can also be viewed in isolation. In each session, cutting-edge research is presented by esteemed researchers from different universities in Europe.
First session: Clinical pharmacology of psychedelics and insights from the limited medical use program in Switzerland
Second session: Preclinical and clinical evidence on mechanisms of action, translational research from Sweden and Denmark
This is the third session in the series.
Views and opinions expressed in these videos are those of the presenters and do not necessarily reflect the official position of ECNP. The content of these videos should not be used in any way as the basis for treatment decisions.
